

Joint Meeting on  
International Conference on  
**PHARMACOLOGY AND TOXICOLOGY**  
&  
18<sup>th</sup> International Conference on  
**MEDICINAL AND PHARMACEUTICAL CHEMISTRY**  
October 18-19, 2018 Dubai, UAE

### Design, synthesis and biological evaluation of new anti-IPF agents


**Lingyu Li**

Chinese Academy of Medical Sciences & Peking Union Medical College, China

**S**tatement of the Problem: Idiopathic Pulmonary fibrosis (IPF) is a severe life-threatening disease with very poor prognosis. IPF patients die within 3 to 5 years after diagnosis mostly due to respiratory failure. To date only 2 small molecule drug (Pirfenidone and Nintedanib) were approved by FDA for IPF treatment, yet they treatment outcome were far from promising. There is an urgent need for novel anti-IPF agents. Methodology & Theoretical

Orientation: Matrine and cinnamic acid was rationally hybrid by amidation reactions. An in vitro anti-fibrotic agent screening model was established based on TGF- $\beta$ 1 induced human fetal lung fibroblast (MRC-5) myofibroblast transformation. Extracellular total collagen accumulation was quantified by Picro-Sirius Red staining. Transient fibroblast and myofibroblast markers (ACTA2, COL1a1, FSP-1, FAP and P-4-H) expression was determined by immunocytochemistry (ICC) methods. Findings: 46 novel matrine-cinnamic acid hybrid compounds were synthesized and evaluated for their anti-fibrotic activity. 10 ng/mL TGF- $\beta$ 1 significantly induces myogenic phenotype formation with elevated extracellular total collagen accumulation and myofibroblast markers expression. Pretreatment of matrine-cinnamic acid hybrid alleviated TGF- $\beta$ 1 induced myogenic transformation. Conclusion & Significance: Compound 3i exhibited an inhibitory effect against TGF- $\beta$ 1 induced total collagen accumulation in MRC-5 fibroblast with the IC<sub>50</sub> value of 1.2 $\mu$ M, which was about 2000 times more potent then Pirfenidone.

3i alleviated TGF- $\beta$ 1 induced extracellular collagen accumulation



### Biography

Lingyu Li is a PhD candidate dedicated in structural modification of bioactive natural products. In searching for novel and promising anti-IPF agents, he has achieved a IPF agent library of more than 100 compounds by semisynthetic methods and established a novel rapid IPF agent screening model.

3143891566@qq.com

### Notes: